Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

Drug Profile

Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

Alternative Names: AZD-9150-sodium; AZD9150; Danvatirsen-sodium; IONIS-STAT3-2.5Rx; IONIS-STAT3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3-2.5Rx; ISIS-STAT3Rx; STAT3Rx

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant ascites; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Phase I/II Liver cancer; Non-Hodgkin's lymphoma
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 28 Aug 2019 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, Second-line therapy or greater) in France (IV)
  • 28 Aug 2019 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, Second-line therapy or greater) in Ireland (IV)
  • 28 Aug 2019 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, Second-line therapy or greater) in Italy (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top